阿托伐他汀对急性冠脉综合征患者血小板及单核细胞表达CD40L、血小板CD62P的影响  

Effect of atorvastatin on the expression of peripheral blood monocytes and platelet CD40L,platelet CD62P in patients with acute coronary syndrome

作　　者：沈凯[1] 袁国裕[1] 陈国雄[1] 俞晓军[1] 王炎一[1] 方波[1] 王红娜[1] 魏峰涛[2] 

机构地区：[1]舟山市人民医院心血管科,浙江舟山316000 [2]山东大学第二医院,济南250033

出　　处：《中国临床药理学杂志》2009年第1期3-5,共3页The Chinese Journal of Clinical Pharmacology

摘　　要：目的观察阿托伐他汀(降血脂药)对急性冠脉综合征患者血小板及单核细胞表达CD40L、血小板CD62P的影响。方法将80例急性冠脉综合征患者随机分成阿托伐他汀组(40例)及常规治疗组(40例),比较观测治疗前及治疗8周后血小板CD62P、血小板及单核细胞表达CD40L。结果治疗后2组血小板及单核细胞表达CD40L、血小板CD62P较治疗前明显降低(P<0.05、P<0.01);治疗后阿托伐他汀组血小板及单核细胞表达CD40L、血小板CD62P较常规组明显降低(P<0.05)。结论在治疗8周后,阿托伐他汀可改善急性冠脉综合征患者的血小板活化功能并显示其有抗炎作用。Objective To investigate the effect of atorvastatin on the expression of peripheral blood monoytes and platelet CD40L, platelet CD62P in patients with acute coronary syndrome. Methods Eighty patients with acute coronary syndrome were randomly divided into atorvastatin therapeutic group （ n = 40） or conventional therapentic group （ n = 40 ）. Before and after 8 weeks of the therapy, levels of peripheral blood monocytes and platelet CD40L ,platelet CD62P were assayed in these two groups. Results After 8 weeks treatment,levels of peripheral blood monocytes and platelet CD40L ,platelet CD62P in two groups were significantly lower than before therapy （P 〈0.05 or P 〈0.01 ）. After 8 weeks of therapy atorvastatin therapentic group were significantly lower than conventional therapeutic group （P 〈 0.05 ）. Conclusion The results suggest that atorvastatin can improve the function of platelet activation factor and resist inflammation.

关 键 词：阿托伐他汀 急性冠脉综合征 免疫介质细胞分化抗原40配体 血小板活化 

分 类 号：R541.4[医药卫生—心血管疾病] R972.6[医药卫生—内科学]